Know Cancer

or
forgot password

Phase 2 Study of Aspirin Plus Exemestane Comparing With Exemestane Alone in the Adjuvant Treatment of Postmenopausal Breast Cancer


Phase 2
50 Years
80 Years
Open (Enrolling)
Female
Breast Neoplasms

Thank you

Trial Information

Phase 2 Study of Aspirin Plus Exemestane Comparing With Exemestane Alone in the Adjuvant Treatment of Postmenopausal Breast Cancer


Inclusion Criteria:



- Breast cancer after surgery postmenopausal

Exclusion Criteria:

- contraindication of aspirin

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Outcome Measure:

Quality of Life

Outcome Time Frame:

4 years

Safety Issue:

Yes

Principal Investigator

Peng Yuan, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Authority:

China: Ethics Committee

Study ID:

CH-BC-011

NCT ID:

NCT01431053

Start Date:

July 2011

Completion Date:

July 2014

Related Keywords:

  • Breast Neoplasms
  • exemestane
  • aspirin
  • quality of life
  • Breast Neoplasms
  • Neoplasms

Name

Location